Combination Gerotherapeutic Interventions for Healthspan Improvement

This study is a 90-day interventional, randomized, controlled pilot trial exploring multi-modal gerotherapies and their impact on longevity-related outcomes. In this proof-of-concept phase, a small sample size of up to 30 subjects (10 subjects in each arm) will be randomized into one of the three arms: 1) Control, 2) Multi-therapy (B12, Naltrexone, Metformin, and NAD+), or 3) Comprehensive Therapy (Rapamycin, Naltrexone, Metformin, B12, NAD+, GSH, and Infinite Supplement).

Inclusion Criteria: * New, existing, or prospective AgelessRx patient * Adults (60-80 years of age) * Any sex * Any ethnicity * Willingness to provide informed consent and complete study assessments/procedures * Willingness to attend virtual meeting check-ins/follow-ups * Willingness and eligibility to take all medications used in this study * Has at-risk indicators for decline on measures of cognitive, immune, and muscle function, as indicated by a combination of BMI of 26-30; SF36 score below the validated central tendency for 2 of: physical function, physical role limitations, energy, pain; final ISQ scores of \